This is definitely the stock to watch. Thanks for the quick summary of the technology. I will need some time to do more research. I think the biggest problem with solid cancers is that the cancer micro-environment is extremely inhibitory, thus it is much easier to treat blood cancer using CAR-cells than solid tumours. See image
below.
CHM seems to have solved the 1st problem of finding a good target for cancer cells. CLTX looks very promising and likely to bind many cancers. Do you know if CHM is:
1) using autologous or allogeneic CAR-T?
2) any other genetic modification like knock-out of: CTLA4, TIM3 or PD-1? I believe other companies are looking at Knock-out of these receptors to produce super potent T cells. However, the risk is increased cytokine release syndrome, which could be fatal in these vulnerable patients.
(20min delay)